We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.
- Authors
Galli, A; Ceni, E; Crabb, D W; Mello, T; Salzano, R; Grappone, C; Milani, S; Surrenti, E; Surrenti, C; Casini, A
- Abstract
Thiazolidinediones (TZD) are a new class of oral antidiabetic drugs that have been shown to inhibit growth of some epithelial cancer cells. Although TZD were found to be ligands for peroxisome proliferators activated receptor gamma (PPARgamma) the mechanism by which TZD exert their anticancer effect is currently unclear. Furthermore, the effect of TZD on local motility and metastatic potential of cancer cells is unknown. The authors analysed the effects of two TZD, rosiglitazone and pioglitazone, on invasiveness of human pancreatic carcinoma cell lines in order to evaluate the potential therapeutic use of these drugs in pancreatic adenocarcinoma.
- Publication
Gut, 2004, Vol 53, Issue 11, p1688
- ISSN
0017-5749
- Publication type
Journal Article
- DOI
10.1136/gut.2003.031997